Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T TradeJuno Therapeutics Inc (NASDAQ:JUNO) is poised to benefit from a rising acquisition trend. Three weeks ago when Gilead Sciences, Inc. (NASDAQ:GILD) announced it would be acquiring smaller rival biopharma name Kite Pharma Inc (NASDAQ:KITE), traders clearly took notice. If Gilead wanted Kite for its CAR-T cancer therapy and Novartis AG (ADR) (NYSE:NVS) recently won the first-ever FDA approval for its CAR-T based oncology drug, there had to be something to it.

Read More At Article Source | Article Attribution